Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Helixmith Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩3,630.00 |
52 Week High | ₩7,440.00 |
52 Week Low | ₩3,250.00 |
Beta | 1.06 |
11 Month Change | -9.59% |
3 Month Change | -18.52% |
1 Year Change | -44.66% |
33 Year Change | -87.95% |
5 Year Change | -96.65% |
Change since IPO | -75.53% |
Recent News & Updates
Shareholder Returns
A084990 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -3.7% | -0.007% | -1.0% |
1Y | -44.7% | 18.6% | 7.4% |
Return vs Industry: A084990 underperformed the KR Biotechs industry which returned 18.6% over the past year.
Return vs Market: A084990 underperformed the KR Market which returned 7.4% over the past year.
Price Volatility
A084990 volatility | |
---|---|
A084990 Average Weekly Movement | 4.7% |
Biotechs Industry Average Movement | 7.5% |
Market Average Movement | 5.0% |
10% most volatile stocks in KR Market | 11.1% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A084990's share price has been volatile over the past 3 months.
Volatility Over Time: A084990's weekly volatility has decreased from 11% to 5% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 61 | Ji-Wook Jeong | www.helixmith.com |
Helixmith Co., Ltd develops biologic and natural nutraceutical products. The company offers LAYLA Tab for osteoarthritis; Allex and Allex i for hypersensitivity improvement; and Mnemosyne for memory improvement. Its lead gene therapy product is Engensis (VM202), which is in a phase III clinical trial for diabetic peripheral neuropathy and diabetic foot ulcer; a phase II clinical trial for amyotrophic lateral sclerosis (ALS) and claudication; and a phase I clinical trial for charcot-marie-tooth disease and coronary artery disease.
Helixmith Co., Ltd Fundamentals Summary
A084990 fundamental statistics | |
---|---|
Market cap | ₩167.15b |
Earnings (TTM) | -₩58.63b |
Revenue (TTM) | ₩3.55b |
47.1x
P/S Ratio-2.9x
P/E RatioIs A084990 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A084990 income statement (TTM) | |
---|---|
Revenue | ₩3.55b |
Cost of Revenue | ₩1.78b |
Gross Profit | ₩1.77b |
Other Expenses | ₩60.40b |
Earnings | -₩58.63b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.27k |
Gross Margin | 49.95% |
Net Profit Margin | -1,652.34% |
Debt/Equity Ratio | 0.1% |
How did A084990 perform over the long term?
See historical performance and comparison